AV-001’s fast track designation follows encouraging results from a Phase I study supporting once-daily dosing and effective Tie2 activation.
FDA Grants Fast Track Designation to AV-001 for Treatment of Moderate to Severe Acute Respiratory Distress Syndrome
Leave a comment
